PatilS, MajumdarB, AwanKH, et al.Cancer oriented biobanks: A comprehensive review. Oncol Rev, 2018; 12:357.
2.
SpeirsV, MorganA. Breast cancer: Investment biobanking—Increased returns from tissue samples. Nat Rev Clin Oncol, 2013; 10:128–129.
3.
VaughtJB. Blood collection, shipment, processing, and storage. Cancer Epidemiol Biomarkers Prev, 2006; 15:1582–1584.
4.
KjellG, RubenG, MadsN, et al.Preanalytical aspects on short- and long-term storage of serum and plasma. Diagnosis, 2019; 6:51–56.
5.
SalminenA, ÅströmP, MetsoJ, et al.Matrix metalloproteinase 8 degrades apolipoprotein A-I and reduces its cholesterol efflux capacity. FASEB J, 2015; 29:1435–1445.
6.
HanemaaijerR, SorsaT, KonttinenYT, et al.Matrix Metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells: Regulation by tumor necrosis factor-alpha and doxycycline. J Biol Chem, 1997; 272:31504–31509.
7.
HalveyP, FarutinV, KoppesL, et al.Variable blood processing procedures contribute to plasma proteomic variability. Clin Proteomics, 2021; 18:5.
8.
NavasA, Giraldo-ParraL, PrietoMD, et al.Phenotypic and functional stability of leukocytes from human peripheral blood samples: Considerations for the design of immunological studies. BMC Immunol, 2019; 20:5.
9.
JonssonA, HjalmarssonC, FalkP, et al.Levels of matrix metalloproteinases differ in plasma and serum—Aspects regarding analysis of biological markers in cancer. Br J Cancer, 2016; 115:703–706.
10.
LeinoA, KoivulaMK. Stability of chemical and immunochemical analytes in uncentrifuged plasma samples. Ann Clin Biochem, 2009; 46:159–161.
11.
OddozeC, LombardE, PortugalH. Stability study of 81 analytes in human whole blood, in serum and in plasma. Clin Biochem, 2012; 45:464–469.
